SCHEMBL66047

SCHEMBL66047

Nc1ncnc2c1ncn2[C@@]1(Cl)C[C@H](O)[C@@H](CO)O1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC28A1 O00337 2/20 0.56
ADORA3 P0DMS8 7/20 0.54
ADORA2A P29274 5/20 0.54
GMPS P49915 1/20 0.48
PI4K2A Q9BTU6 4/20 0.48
PI4KA P42356 3/20 0.48
PI4K2B Q8TCG2 3/20 0.48
PI4KB Q9UBF8 3/20 0.48
ADORA2B P29275 2/20 0.48
DPP4 P27487 1/20 0.48
MEN1 O00255 1/20 0.48
MAP3K7 O43318 1/20 0.48
SLC28A2 O43868 1/20 0.48
GAPDH P04406 1/20 0.48
MAPK1 P28482 1/20 0.48
ADORA1 P30542 1/20 0.48
STAT6 P42226 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
DOT1L Q8TEK3 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29745935 1.00 SLC28A1 (0.56) SLC28A1ADORA3ADORA2AGMPSPI4K2A
SCHEMBL2335292 0.85 SLC28A1 (0.57) SLC28A1ADORA3ADORA2AGMPSPI4K2A
SCHEMBL29362292 0.85 SLC28A1 (0.57) SLC28A1ADORA3ADORA2AGMPSPI4K2A
SCHEMBL6756465 0.85 SLC28A1 (0.57) SLC28A1ADORA3ADORA2AGMPSPI4K2A
SCHEMBL9956204 0.85 SLC28A1 (0.57) SLC28A1ADORA3ADORA2AGMPSPI4K2A
SCHEMBL3466617 0.84 SLC28A1 (0.56) SLC28A1ADORA3ADORA2AGMPSPI4K2A
SCHEMBL29459696 0.84 SLC28A1 (0.56) SLC28A1ADORA3ADORA2AGMPSPI4K2A
SCHEMBL30822754 0.84 SLC28A1 (0.56) SLC28A1ADORA3ADORA2AGMPSPI4K2A
SCHEMBL439243 0.84 SLC28A1 (0.56) SLC28A1ADORA3ADORA2AGMPSPI4K2A
SCHEMBL29799646 0.84 SLC28A1 (0.56) SLC28A1ADORA3ADORA2AGMPSPI4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2135 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4711364-A1 FUSED PYRROLE RING OR FUSED PYRIDINE RING COMPOUND Pharmaengine, Inc. (TW) 2026-03-18 EP claimed
EP-4701737-A2 MTA-COOPERATIVE PRMT5 INHIBITOR Pharmaengine, Inc. (TW) 2026-03-04 EP claimed
WO-2025077721-A1 MYT1 INHIBITOR BASED ON FUSED THIAZOLE OR PYRIDINE RING PHARMAENGINE, INC. (CN) 2025-04-17 WO claimed
CN-119798282-A Fused pyridine ring-based Myt1 inhibitors 智擎生技制药股份有限公司 2025-04-11 CN claimed
WO-2024222914-A2 MTA-COOPERATIVE PRMT5 INHIBITOR PHARMAENGINE, INC. (CN) 2024-10-31 WO claimed
WO-2023130012-A1 COMPOUNDS FOR MUTANT KRAS PROTEIN DEGRADATION AND USES THEREOF DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2023-07-06 WO claimed
EP-3544685-B1 HETROARYLAMINE COMPOUNDS FOR MODULATING THE HEDGEHOG PATHWAY AND PREPARING METHOD AND USES THEREOF DEV CT BIOTECHNOLOGY (TW) 2023-01-04 EP claimed
EP-3411036-B1 3,5-DISUBSTITUTED PYRAZOLES USEFUL AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATIONS AND APPLICATIONS PHARMAENGINE INC (TW) 2021-12-29 EP claimed
EP-3925625-A1 HYDROPHOBIC MOLECULE-INDUCED BRANCHED POLYMER AGGREGATES AND THEIR USE ANP Technologies, Inc. (US) 2021-12-22 EP claimed
WO-2021222138-A1 COMPOUNDS FOR MUTANT RAS PROTEIN DEGRADATION DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2021-11-04 WO claimed
US-20040241717-A1 Oligomeric compounds for the modulation of thioredoxin expression SANTARIS PHARMA A/S 2004-12-02 US claimed
WO-2004083430-A2 SHORT INTERFERING RNA (siRNA) ANALOGUES SANTARIS PHARMA A/S (DK) 2004-09-30 WO claimed
WO-2004069992-A2 OLIGOMERIC COMPOUNDS FOR THE MODULATION OF RAS EXPRESSION SANTARIS PHARMA A/S (DK) 2004-08-19 WO claimed
WO-2004069991-A2 OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION SANTARIS PHARMA A/S (DK) 2004-08-19 WO claimed
WO-2004069990-A2 OLIGOMERIC COMPOUNDS FOR THE MODULATION OF THIOREDOXIN EXPRESSION SANTARIS PHARMA A/S (DK) 2004-08-19 WO claimed
US-20040138140-A1 Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapy TELIK, INC. 2004-07-15 US claimed
WO-2004045593-A2 COMBINATION CANCER THERAPY WITH A GST-ACTIVATED ANTICANCER COMPOUND AND ANOTHER ANTICANCER THERAPY TELIK, INC. (US) 2004-06-03 WO claimed
WO-2004020468-A2 INTERFERON BETA-LIKE MOLECULES FOR TREATMENT OF CANCER MAXYGEN APS (DK) 2004-03-11 WO claimed
WO-2003061703-A9 METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS WITH STATINS NOVIMMUNE SA (CH) 2003-12-24 WO claimed
WO-1996005865-A1 COMBINATION IMMUNOTOXIN/ANTINEOPLASTIC AGENT THERAPY FOR B-LINEAGE CANCER REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1996-02-29 WO claimed